Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells

Fig. 3

Inhibition of autophagy sensitized the inhibitory effects of anlotinib on human lung cancer cells a, Representative images of fluorescent LC3-II puncta as analyzed by confocal microscopy after anlotinib 20 μM treatment with or without autophagy inhibitor (CQ 25 μM and 3-MA 5 mM) for 24 h. b, The expressions of beclin-1 and LC3-I/II were detected using western blotting after treatment with anlotinib (20 μM) with or without 3-MA 5 mM or CQ 25 μM for 24 h. c, Suppression of autophagy with CQ 25 μM or 3-MA 5 mM decreased the viability of anlotinib-treated cells. d, The effects of cell viability after exposure to anlotinib (20 μM) with beclin-1 knockdown or siRNA negative control. e, Flow cytometry showed that inhibition of autophagy with CQ 25 μM or 3-MA 5 mM increased anlotinib (20 μM)-cultured cell apoptosis. Values are presented in means ± SD from three independent experiments. n/s no significant, *P < 0.05, **P < 0.01. Scale bar: 20 μm

Back to article page